324 related articles for article (PubMed ID: 24346811)
21. Paliperidone extended release.
Yang LP; Plosker GL
CNS Drugs; 2007; 21(5):417-25; discussion 426-7. PubMed ID: 17447829
[TBL] [Abstract][Full Text] [Related]
22. Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents.
Kim EY; Chang SM; Shim JC; Joo EJ; Kim JJ; Kim YS; Ahn YM
Curr Med Res Opin; 2013 Oct; 29(10):1231-40. PubMed ID: 23777311
[TBL] [Abstract][Full Text] [Related]
23. Serum concentrations of paliperidone versus risperidone and clinical effects.
Nazirizadeh Y; Vogel F; Bader W; Haen E; Pfuhlmann B; Gründer G; Paulzen M; Schwarz M; Zernig G; Hiemke C
Eur J Clin Pharmacol; 2010 Aug; 66(8):797-803. PubMed ID: 20358189
[TBL] [Abstract][Full Text] [Related]
24. [Paliperidone, risperidone].
Takeuchi K; Sanjo K; Sakai A
Nihon Rinsho; 2013 Apr; 71(4):654-9. PubMed ID: 23678595
[TBL] [Abstract][Full Text] [Related]
25. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
Kramer M; Simpson G; Maciulis V; Kushner S; Vijapurkar U; Lim P; Eerdekens M
J Clin Psychopharmacol; 2007 Feb; 27(1):6-14. PubMed ID: 17224706
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
Marder SR; Kramer M; Ford L; Eerdekens E; Lim P; Eerdekens M; Lowy A
Biol Psychiatry; 2007 Dec; 62(12):1363-70. PubMed ID: 17601495
[TBL] [Abstract][Full Text] [Related]
27. Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release.
Boom S; Talluri K; Janssens L; Remmerie B; De Meulder M; Rossenu S; van Osselaer N; Eerdekens M; Cleton A
J Clin Pharmacol; 2009 Nov; 49(11):1318-30. PubMed ID: 19713555
[TBL] [Abstract][Full Text] [Related]
28. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.
Arakawa R; Ito H; Takano A; Takahashi H; Morimoto T; Sassa T; Ohta K; Kato M; Okubo Y; Suhara T
Psychopharmacology (Berl); 2008 Apr; 197(2):229-35. PubMed ID: 18058087
[TBL] [Abstract][Full Text] [Related]
29. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets.
Berwaerts J; Cleton A; Herben V; van de Vliet I; Chang I; van Hoek P; Eerdekens M
Pharmacopsychiatry; 2009 Jul; 42(4):158-63. PubMed ID: 19585395
[TBL] [Abstract][Full Text] [Related]
30. Paliperidone-ER: first atypical antipsychotic with oral extended release formulation.
Lautenschlager M; Heinz A
Expert Rev Neurother; 2008 Feb; 8(2):193-200. PubMed ID: 18271706
[TBL] [Abstract][Full Text] [Related]
31. Remission of drug-induced hepatitis after switching from risperidone to paliperidone.
Paulzen M; Orfanos S; Gründer G
Am J Psychiatry; 2010 Mar; 167(3):351-2. PubMed ID: 20194492
[No Abstract] [Full Text] [Related]
32. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
[TBL] [Abstract][Full Text] [Related]
33. QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone.
Suzuki Y; Fukui N; Watanabe J; Ono S; Sugai T; Tsuneyama N; Saito M; Inoue Y; Someya T
Hum Psychopharmacol; 2012 Jan; 27(1):39-42. PubMed ID: 22144033
[TBL] [Abstract][Full Text] [Related]
34. Dose pattern and effectiveness of paliperidone extended-release tablets in patients with schizophrenia.
Lee JS; Ahn JH; Lee JI; Kim JH; Jung I; Lee CU; Lee JY; Lee SI; Kim CY
Clin Neuropharmacol; 2011; 34(5):186-90. PubMed ID: 21725234
[TBL] [Abstract][Full Text] [Related]
35. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study.
Uchida H; Mamo DC; Pollock BG; Suzuki T; Tsunoda K; Watanabe K; Mimura M; Bies RR
Ther Drug Monit; 2012 Apr; 34(2):182-7. PubMed ID: 22377743
[TBL] [Abstract][Full Text] [Related]
36. Paliperidone extended-release: does it have a place in antipsychotic therapy?
Gahr M; Kölle MA; Schönfeldt-Lecuona C; Lepping P; Freudenmann RW
Drug Des Devel Ther; 2011 Mar; 5():125-46. PubMed ID: 21448450
[TBL] [Abstract][Full Text] [Related]
37. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.
Kane J; Canas F; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
Schizophr Res; 2007 Feb; 90(1-3):147-61. PubMed ID: 17092691
[TBL] [Abstract][Full Text] [Related]
38. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Li H; Rui Q; Ning X; Xu H; Gu N
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
[TBL] [Abstract][Full Text] [Related]
39. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone.
Canuso CM; Grinspan A; Kalali A; Damaraju CV; Merriman U; Alphs L; Awad AG
Int Clin Psychopharmacol; 2010 May; 25(3):155-64. PubMed ID: 20216424
[TBL] [Abstract][Full Text] [Related]
40. Paliperidone extended release: in adolescents with schizophrenia.
Perry CM
Paediatr Drugs; 2012 Dec; 14(6):417-27. PubMed ID: 23050744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
